Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells.

导出 OA

翻译打印收藏纠错

作者： Maria-Luisa,del Rio ^[1] ; Carlos,Fernandez-Renedo ^[1] ; Olivier,Chaloin ^[2] ; Stefanie,Scheu ^[3] ; Klaus,Pfeffer ^[3] ; Yasushi,Shintani ^[4] ; Jose-Antonio,Perez-Simon ^[5] ; Pascal,Schneider ^[6] ; Jose-Ignacio,Rodriguez-Barbosa ^[1]

作者单位： a Transplantation Immunobiology Section, Institute of Biomedicine, University of Leon and Castilla and Leon Regional Transplantation Coordination, Leon University Hospital , Leon , Spain. ^[1] b CNRS UPR 3572, IBMC, Immunopathologie et Chimie Thérapeutique, 15 rue René Descartes , Strasbourg , France. ^[2] c Institute of Medical Microbiology and Hospital Hygiene, University of Duesseldorf, Universitaetsstr. 1, Geb. 22.21 , Duesseldorf , D-40225 Germany. ^[3] d Department of International Affairs , Japan Science and Technology Agency, K´s Gobancho 7 , Gobancho Chiyoda-Ku , Tokyo , 102-0076 , Japan. ^[4] e Department of Hematology , University Hospital Virgen del Rocio / Institute of Biomedicine (IBIS / CSIC) , Sevilla , Spain. ^[5] f Department of Biochemistry , University of Lausanne , 1066 Epalinges , Switzerland. ^[6]

关键词 Alloreactivity CD258)CD270)DcR3 (TNFRSF6b)HVEM (TNFRSF14 LIGHT (TNFSF14 LTβR (TNFRSF3)co-stimulation cytotoxicity graft rejection graft-vs.-host disease transplantation